In 2024, the value of biopharma nonprofit deals is tracking slightly higher than the previous year, but still significantly lower than the value seen in prior years. Meanwhile, grants to biopharma firms have dropped by more than 50% compared to last year’s monthly average. The U.S. Department of Defense emerged as the leading grant issuer to biopharma firms, and also saw the highest-value nonprofit deal in the sector.